ReLaPSe: Prospective Study Evaluating The Treatment Outcomes For Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Retroperitoneal liposarcoma is a rare type of soft tissue cancer that develops in the fat behind the abdominal organs. Even after successful surgery, it frequently comes back — and when it does, treating the recurrence remains one of the most challenging problems in surgical oncology. There is currently limited high-quality data to guide treatment decisions for recurrent disease. This observational study will collect prospective data on patients with first-time local recurrence of retroperitoneal liposarcoma who are having further surgery with curative intent, with or without radiotherapy or chemotherapy as recommended by their multidisciplinary team. No experimental treatments are involved — participants will receive whatever their doctors recommend as standard of care. The data collected will help validate a tool designed to predict individual patient outcomes. You may be eligible if you are aged 18 or older with a first recurrence of well-differentiated or dedifferentiated retroperitoneal or pelvic liposarcoma after a previous complete surgical removal, with no distant spread on imaging, and your tumour is considered resectable by your surgical team. Quality of life questionnaires will be completed at several time points.